Novocure Ltd NVCR

Healthcare Medical Devices

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

NDAQ:NVCR - Post by User

Novocure Ltd

<< Previous

Bullboard Posts

Post by whytestockson Oct 15, 2024 5:00pm

45 Views

Post# 36267093

FDA Approves Novocure's Optune Lua® for the Treatment o

Just In: $NVCR FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung CancerThe first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or after a platinum-based regimen Results of the pivotal Phase 3 LUNAR trial represent the first ...NVCR - FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

<< Previous

Bullboard Posts

Understanding tax loss season and the “Santa Claus rally”